Rachel Schiff

24.3k total citations · 6 hit papers
171 papers, 15.1k citations indexed

About

Rachel Schiff is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Rachel Schiff has authored 171 papers receiving a total of 15.1k indexed citations (citations by other indexed papers that have themselves been cited), including 113 papers in Oncology, 74 papers in Molecular Biology and 69 papers in Genetics. Recurrent topics in Rachel Schiff's work include HER2/EGFR in Cancer Research (85 papers), Estrogen and related hormone effects (66 papers) and Monoclonal and Polyclonal Antibodies Research (32 papers). Rachel Schiff is often cited by papers focused on HER2/EGFR in Cancer Research (85 papers), Estrogen and related hormone effects (66 papers) and Monoclonal and Polyclonal Antibodies Research (32 papers). Rachel Schiff collaborates with scholars based in United States, Italy and Switzerland. Rachel Schiff's co-authors include C. Kent Osborne, Suleiman Massarweh, Jiang Shou, Grazia Arpino, Mothaffar F. Rimawi, Carolina Gutiérrez, Susan G. Hilsenbeck, Carmine De Angelis, Adrian V. Lee and C. Kent Osborne and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Rachel Schiff

169 papers receiving 14.9k citations

Hit Papers

Mechanisms of Tamoxifen Resistance: Increased Estrogen Re... 1998 2026 2007 2016 2004 2010 1998 2011 2011 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer
    2004 918 citations Suleiman Massarweh, Rachel Schiff et al. profile →
  2. Mechanisms of Endocrine Resistance in Breast Cancer
    2010 877 citations C. Kent Osborne, Rachel Schiff Annual Review of Medicine profile →
  3. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
    1998 550 citations Rachel Schiff, Susan G. Hilsenbeck et al. profile →
  4. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo
    2011 473 citations Xiaoyong Fu, Rachel Schiff et al. profile →
  5. HER2: Biology, Detection, and Clinical Implications
    2011 456 citations Carolina Gutiérrez, Rachel Schiff profile →
  6. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
    2015 454 citations Rinath Jeselsohn, Carmine De Angelis et al. profile →

Peers

Rachel Schiff
Bryan T. Hennessy Ireland
Dennis C. Sgroi United States
Jonathan W. Simons United States
C. David James United States
Britta Weigelt United States
Christopher C. Benz United States
C. Kent Osborne United States
John W.M. Martens Netherlands
Rameen Beroukhim United States
Rosette Lidereau France
Bryan T. Hennessy Ireland
Rachel Schiff
Citations per year, relative to Rachel Schiff Rachel Schiff (= 1×) peers Bryan T. Hennessy

Countries citing papers authored by Rachel Schiff

Since Specialization
Citations

This map shows the geographic impact of Rachel Schiff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Schiff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Schiff more than expected).

Fields of papers citing papers by Rachel Schiff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Schiff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Schiff. The network helps show where Rachel Schiff may publish in the future.

Co-authorship network of co-authors of Rachel Schiff

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Schiff. A scholar is included among the top collaborators of Rachel Schiff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Schiff. Rachel Schiff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Xian, Jamunarani Veeraraghavan, Lanfang Qin, et al.. (2021). Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clinical Cancer Research. 27(9). 2648–2662. 8 indexed citations
2.
Giuliano, Mario, Hin Ching Lo, Grazia Arpino, et al.. (2018). Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. Cancer Research. 78(4). 845–852. 153 indexed citations
3.
Zhang, Zhuo, Rajani Rajbhandari, Tiffiny S. Cooper, et al.. (2018). Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition. Molecular Cancer Therapeutics. 17(5). 921–930. 14 indexed citations
4.
Wu, Yanming, Zhao Zhang, Cecilia J. Proietti, et al.. (2017). Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2–ERα–GREB1 Transcriptional Axis. Cancer Research. 78(3). 671–684. 80 indexed citations
5.
Malorni, Luca, Mario Giuliano, Ilenia Migliaccio, et al.. (2016). Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Molecular Cancer Research. 14(5). 470–481. 31 indexed citations
6.
Marusyk, Andriy, Doris P. Tabassum, Michalina Janiszewska, et al.. (2016). Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Research. 76(22). 6495–6506. 96 indexed citations
7.
Kim, Jinah, Meenakshi Anurag, Jamunarani Veeraraghavan, et al.. (2016). Amplification of TLK2 Induces Genomic Instability via Impairing the G2–M Checkpoint. Molecular Cancer Research. 14(10). 920–927. 22 indexed citations
8.
Rimawi, Mothaffar F., Rachel Schiff, & C. Kent Osborne. (2015). Targeting HER2 for the Treatment of Breast Cancer. Annual Review of Medicine. 66(1). 111–128. 208 indexed citations
9.
Chung, Alice, Michael Choi, Shikha Bose, et al.. (2015). Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer. Clinical Breast Cancer. 15(6). 448–457.e2. 9 indexed citations
10.
Morrison, Gladys, Xiaoyong Fu, Martin J. Shea, et al.. (2014). Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Research and Treatment. 144(2). 263–272. 39 indexed citations
11.
Fu, Xiaoyong, C. Kent Osborne, & Rachel Schiff. (2013). Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. The Breast. 22. S12–S18. 64 indexed citations
12.
Rimawi, Mothaffar F., Ingrid A. Mayer, Andres Forero, et al.. (2013). Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006. Journal of Clinical Oncology. 31(14). 1726–1731. 187 indexed citations
13.
Welsh, Allison W., Donald R. Lannin, Gregory Young, et al.. (2011). Cytoplasmic Estrogen Receptor in Breast Cancer. Clinical Cancer Research. 18(1). 118–126. 49 indexed citations
14.
Kretzer, Nicole M., Milu T. Cherian, Chengjian Mao, et al.. (2010). A Noncompetitive Small Molecule Inhibitor of Estrogen-regulated Gene Expression and Breast Cancer Cell Growth That Enhances Proteasome-dependent Degradation of Estrogen Receptor α. Journal of Biological Chemistry. 285(53). 41863–41873. 18 indexed citations
15.
Rimawi, Mothaffar F., Lisa Wiechmann, Yen-Chao Wang, et al.. (2010). Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts. Clinical Cancer Research. 17(6). 1351–1361. 66 indexed citations
16.
Massarweh, Suleiman, C. Kent Osborne, Chad J. Creighton, et al.. (2008). Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function. Cancer Research. 68(3). 826–833. 375 indexed citations
17.
Kang, Yun Kyoung, Rachel Schiff, Lan Ko, et al.. (2008). Dual Roles for Coactivator Activator and its Counterbalancing Isoform Coactivator Modulator in Human Kidney Cell Tumorigenesis. Cancer Research. 68(19). 7887–7896. 20 indexed citations
18.
Creighton, Chad J., Suleiman Massarweh, Shixia Huang, et al.. (2008). Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts. Cancer Research. 68(18). 7493–7501. 101 indexed citations
19.
Kim, Sung Hoon, Cory C. Funk, Zeynep Madak‐Erdogan, et al.. (2005). Estrogen Dendrimer Conjugates that Preferentially Activate Extranuclear, Nongenomic Versus Genomic Pathways of Estrogen Action. Molecular Endocrinology. 20(3). 491–502. 211 indexed citations
20.
Schiff, Rachel, Suleiman Massarweh, Jiang Shou, & C. Kent Osborne. (2003). Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.. PubMed. 9(1 Pt 2). 447S–54S. 250 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bryan T. Hennessy Breakdown of academic impact, for papers by Dennis C. Sgroi Breakdown of academic impact, for papers by Jonathan W. Simons Breakdown of academic impact, for papers by C. David James Breakdown of academic impact, for papers by Britta Weigelt Breakdown of academic impact, for papers by Christopher C. Benz Breakdown of academic impact, for papers by C. Kent Osborne Breakdown of academic impact, for papers by John W.M. Martens Breakdown of academic impact, for papers by Rameen Beroukhim Breakdown of academic impact, for papers by Rosette Lidereau
Rankless by CCL
2026